Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3849914 | American Journal of Kidney Diseases | 2010 | 27 Pages |
Abstract
The KDIGO guideline addresses the evaluation and treatment of abnormalities of CKD-MBD in adults and children with CKD stages 3-5 on long-term dialysis therapy or with a kidney transplant. Tests considered are those that relate to laboratory, bone, and cardiovascular abnormality detection and monitoring. Treatments considered are interventions to treat hyperphosphatemia, hyperparathyroidism, and bone disease in patients with CKD stages 3-5D and 1-5T. Limitations of the evidence are discussed. The lack of definitive clinical outcome trials explains why most recommendations are not of level 1 but of level 2 strength, which means weak or discretionary recommendations. Suggestions for future research highlight priority areas.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Katrin MD, MS, Jeffrey S. MD, Bryan MD, MS, Raj MBBS, Mary B. MD, Kevin J. MB, BCh, Stuart M. DO, Stanley MD,